<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024058</url>
  </required_header>
  <id_info>
    <org_study_id>CQGE031E12301</org_study_id>
    <secondary_id>2020-003018-11</secondary_id>
    <nct_id>NCT05024058</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines</brief_title>
  <acronym>PEARL-PROVOKE</acronym>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Inducible Urticaria (CINDU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo controlled, phase 3 study designed to evaluate the efficacy and safety of&#xD;
      ligelizumab in participants with chronic inducible urticaria who are inadequately controlled&#xD;
      with H1-antihistamines&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are currently no approved therapies for patients with CINDU who remain symptomatic&#xD;
      despite treatment with H1-antihistamines. The purpose of this study is to establish efficacy&#xD;
      and safety of ligelizumab (QGE031) over placebo in participants with chronic inducible&#xD;
      urticaria (CINDU) who remain symptomatic despite treatment with H1 antihistamine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 9, 2021</start_date>
  <completion_date type="Anticipated">December 27, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Total Fric Score in participants with symptomatic dermographism</measure>
    <time_frame>Week 12</time_frame>
    <description>Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in critical temperature threshold in participants with cold urticaria</measure>
    <time_frame>Week 12</time_frame>
    <description>The Temptest is used to induce itch and hives in participants with cold urticaria. Critical temperature threshold (CTT), as measured by the Temptest, determines the highest temperature sufficient for inducing symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in itch numerical rating scale in participants with cholinergic urticaria</measure>
    <time_frame>Week 12</time_frame>
    <description>Itch numerical rating scale, a scale from 0 to 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with symptomatic dermographism with Total Fric score = 0</measure>
    <time_frame>Week 12</time_frame>
    <description>Total Fric score, a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in itch numerical rating scale in participants with symptomatic dermographism</measure>
    <time_frame>Week 12</time_frame>
    <description>Itch numerical rating scale, a scale from 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with cold urticaria with complete response (no itch or hives) to the TempTest</measure>
    <time_frame>Week 12</time_frame>
    <description>The Temptest is used to induce itch and hives in participants with cold urticaria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in itch numerical rating scale in participants with cold urticaria</measure>
    <time_frame>Week 12</time_frame>
    <description>Itch numerical rating scale, a scale from 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with cholinergic urticaria with itch numerical rating scale =0</measure>
    <time_frame>Week 12</time_frame>
    <description>Itch numerical rating scale, a scale from 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with cholinergic urticaria with physician global assessment of severity of hives (PGA - hive score) =0</measure>
    <time_frame>Week 12</time_frame>
    <description>Physician global assessment of severity of hives</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment emergent adverse events and serious adverse events during the study</measure>
    <time_frame>Week 24</time_frame>
    <description>Treatment emergent adverse events and serious adverse events are those which occur at any time only after treatment has started</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">438</enrollment>
  <condition>Chronic Inducible Urticaria</condition>
  <arm_group>
    <arm_group_label>Ligelizumab low dose, symptomatic dermographism group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ligelizumab low dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ligelizumab high dose, symptomatic dermographism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ligelizumab high dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC q4W, symptomatic dermographism</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injection every 4 weeks in participants with symptomatic dermographism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ligelizumab low dose, cold urticaria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ligelizumab low dose subcutaneous injection every 4 weeks in participants with cold urticaria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ligelizumab high dose, cold urticaria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cold urticaria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC q4w, cold urticaria</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injection every 4 weeks in participants with cold urticaria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ligelizumab high dose, cholinergic urticaria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cholinergic urticaria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC q4w, cholinergic urticaria</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injections every 4 weeks in participants with cholinergic urticaria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ligelizumab</intervention_name>
    <description>Ligelizumab treated groups and arms</description>
    <arm_group_label>Ligelizumab high dose, cholinergic urticaria</arm_group_label>
    <arm_group_label>Ligelizumab high dose, cold urticaria</arm_group_label>
    <arm_group_label>Ligelizumab high dose, symptomatic dermographism</arm_group_label>
    <arm_group_label>Ligelizumab low dose, cold urticaria</arm_group_label>
    <arm_group_label>Ligelizumab low dose, symptomatic dermographism group</arm_group_label>
    <other_name>QGE031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo treated groups and arms</description>
    <arm_group_label>Placebo SC q4W, symptomatic dermographism</arm_group_label>
    <arm_group_label>Placebo SC q4w, cholinergic urticaria</arm_group_label>
    <arm_group_label>Placebo SC q4w, cold urticaria</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed CINDU diagnosis (as per guidelines) for symptomatic dermographism, cold&#xD;
             urticaria or cholinergic urticaria for â‰¥ 4 months.&#xD;
&#xD;
               -  Diagnosis of CINDU (symptomatic dermographism, cold urticaria or cholinergic&#xD;
                  urticaria) inadequately controlled with H1-AH at local label approved doses at&#xD;
                  the time of randomization, as defined by all of the following:&#xD;
&#xD;
               -  Positive response (i.e development of symptoms) to triggers despite treatment&#xD;
                  with H1-AH&#xD;
&#xD;
               -  Positive response (i.e. development of symptoms) to provocation test on day of&#xD;
                  randomization&#xD;
&#xD;
               -  Participants must be able to physically perform the protocol defined provocation&#xD;
                  test specific to the participant's CINDU.&#xD;
&#xD;
               -  Cholinergic urticaria participants must show sweating in performing the&#xD;
                  pulse-controlled ergometry test on day of randomization. Participants with&#xD;
                  anhidrosis must not be included.&#xD;
&#xD;
               -  Willing and able to complete a daily symptom eDiary as per protocol requirement&#xD;
                  and adhere to the study visit schedules&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to any of the study drugs or its components or to drugs of&#xD;
             similar chemical classes or to the provocation test or items used in provocation tests&#xD;
&#xD;
               -  Participants who have concomitant CSU at screening&#xD;
&#xD;
               -  Participants who have a familial form of the target CINDU that is being&#xD;
                  considered for the participant's inclusion in this study&#xD;
&#xD;
               -  Participants having a more defined other form of inducible urticaria than the&#xD;
                  target CINDU that is being considered for the participant's inclusion in this&#xD;
                  study&#xD;
&#xD;
               -  Diseases, other than chronic inducible urticaria, with urticarial or angioedema&#xD;
                  symptoms such as urticarial vasculitis, erythema multiforme, cutaneous&#xD;
                  mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema (eg,&#xD;
                  due to C1 inhibitor deficiency).&#xD;
&#xD;
               -  Any other skin disease associated with chronic itching that might influence, in&#xD;
                  the investigator's opinion, the study evaluations and results (eg, atopic&#xD;
                  dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.)&#xD;
                  or skin diseases associated with only wheals and no itch e.g asymptomatic&#xD;
                  dermographism&#xD;
&#xD;
               -  Prior exposure to ligelizumab, omalizumab and or other anti-IgE therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ligelizumab</keyword>
  <keyword>anti-IgE</keyword>
  <keyword>CINDU</keyword>
  <keyword>chronic inducible urticaria</keyword>
  <keyword>symptomatic dermographism</keyword>
  <keyword>cold urticaria</keyword>
  <keyword>cholinergic urticaria</keyword>
  <keyword>urticaria</keyword>
  <keyword>itch</keyword>
  <keyword>hives</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Chronic Urticaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

